DoubleLine Securitized Credit ETF DSCO
24.40 USD -0.04 (-0.16%)
At closeNov 11, 2026, 4:00 PM EST
24.40 0.00 0.00%
After hours · Nov 11, 4:00 PM ET
24.34 Day range 24.42
24.28 52-week range 25.34
- YTD
- -2.56%
- 1 year
- -2.56%
News
benzinga.com ETF-ization Accelerates: SEC Share-Class Relief Puts Trillions In Mutual Fund Assets In Play ETF conversions have surpassed 200 in the past 5 years. as SEC share-class relief opens new opportunities for mutual fund managers to expand into ETFs.
benzinga.com New DLUX ETF Targets Ultrashort Bonds Amid Interest Rate Volatility, Fed Pivot Debate DLUX ETF offers an ultrashort bond strategy, aiming to deliver yield and stability as interest rate uncertainty and Fed policy risks keep markets on edge.
etftrends.com DoubleLine Expands Active ETF Suite With Ultrashort Income Strategy DoubleLine has launched the DoubleLine Ultrashort Income ETF (DLUX), an active ETF designed to optimize returns while maintaining high liquidity and low interest-rate risk. Priced at 18 basis points,…
benzinga.com DoubleLine Converts Mutual Fund Into ETF — Here's Why It Matters For Bond Investors DoubleLine has launched the DSCO ETF after converting its mutual fund, offering investors new access to securitized credit income beyond traditional bonds.
etftrends.com Mutual Fund to ETF Conversion Data Boosts Active Fixed Income ETF Case Key trends like AI investing, geopolitical risk, and Fed narratives all dominate the market headlines. However, savvy investors know that sometimes, the big stories fly under the radar.
benzinga.com Earnings Scheduled For March 24, 2016 
benzinga.com Discovery Labs Announces Beginning of AEROSURF Phase 2b Clinical Trial For Premature Infants 26-32 Weeks Old 
benzinga.com Results of AEROSURF Phase 2a Clinical Program in Premature Infants 29 to 34 Weeks Gestational Age Presented at the 2015 Hot Topics in Neonatology Annual Meeting-, Overall Safety And Tolerability Profile Of AEROSurf Group Comparable To Control Group 
benzinga.com US Stock Futures Flat Ahead Of Jobless Claims - benzinga.com Discovery Labs Reports Encouraging Results for AEROSURF Phase 2a Clinical Program in Premature Infants 29-34 Weeks
benzinga.com Earnings Scheduled For August 10, 2015 
benzinga.com Stocks Hitting 52-Week Lows - benzinga.com US Stock Futures Flat; All Eyes On Fed Minutes
benzinga.com Discovery Labs Reports Enrollment of First Patient in AEROSURF Phase 2a Dose Expansion Trial - benzinga.com Discovery Labs Says Key Objectives of Phase 2a Clinical Trial of AEROSURF Were Achieved
- benzinga.com Stocks Hitting 52-Week Lows
- benzinga.com Morning Market Losers
benzinga.com Morning Market Losers - benzinga.com Earnings Scheduled For March 16, 2015
benzinga.com Discovery Laboratories Sees Mystery In Recent Stock Gyrations - benzinga.com Earnings Scheduled For November 6, 2014
- benzinga.com Discovery Labs Announces Organizational Change and Enhanced Expertise in Neonatology
benzinga.com Discovery Labs Collaborates With Battelle on AEROSURF Program - benzinga.com Discovery Laboratories, Inc. Reports Q2 EPS of $(0.14) vs $(0.15) Est
- benzinga.com Discovery Laboratories, Inc. Reports Q1 EPS of $(0.14) vs $(0.13) Est
- benzinga.com Revenues Decline at Discovery Labs in Q4, Shares Down - Analyst Blog
- benzinga.com Discovery Laboratories, Inc. Reports Q4 EPS of $(0.16), Inline
- benzinga.com Earnings Scheduled For November 12, 2013
- benzinga.com UPDATE: Piper Jaffray Initiates Coverage on Discovery Laboratories on Emerging Respiratory Franchise at Breathtaking Value
- benzinga.com Benzinga's Top Initiations
- benzinga.com Discovery Labs Reports IND Submission for AEROSURF, Sees Neonatal Program Starting Q4
- benzinga.com Morning Market Movers
- benzinga.com Discovery Labs Reports FDA Approval of SURFAXIN's Updated Specs
- benzinga.com Discovery Laboratories, Inc. Reports Q2 EPS of $(0.22) vs $(0.28) Est
- benzinga.com Discovery Labs Issues Final Assessment of Reintubation on Healthcare Costs, Says Infants Treated with Surfaxin Survival Higher without Intubation
- benzinga.com UPDATE: Discovery Labs Responds to FDA Request for Clarification of Recently Submitted SURFAXIN(R) (lucinactant) Updated Product Specifications
- benzinga.com Stocks Hitting 52-Week Lows
- benzinga.com Discovery Laboratories, Inc. Reports Q1 EPS of $(0.29) vs $(0.26) Est
- benzinga.com Discovery Laboratories, Inc. Reports Q4 EPS of $(0.16) vs $(0.28) Est
- benzinga.com Earnings Scheduled For March 13, 2013
- benzinga.com Benzinga's Small Cap Movers for Thursday February 14, 2013
- benzinga.com Shares of Discovery Labs Rally Sharply as Co. Receives $30M Funding Commitment from Deerfield
- benzinga.com Discovery Labs Receives US Patent for Pulmonary Surfactant Formulations
- benzinga.com Discovery Labs Launches AFECTAIR
- benzinga.com Discovery Labs Launches AFECTAIR for Infants
- benzinga.com Discovery Labs Offers Data Showing Lower Rate of Reintubation Observed with SURFAXIN Treatment
- benzinga.com Discovery Labs Provides Commercial Update for SURFAXIN and AFECTAIR: Method to Assess Conformance Needs Improvment
- benzinga.com Discovery Labs Provides Commercial Update for SURFAXIN, AFECTAIR
- benzinga.com UPDATE: Stifel Nicolaus Initiates Discovery Laboratories at Buy with $5 PT
- benzinga.com Benzinga's Top Initiations